Seres Therapeutics, Inc. — Director's Dealing 2016

Feb 3, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Seres Therapeutics, Inc. (MCRB)
CIK: 0001609809
Period of Report: 2016-02-01

Reporting Person: Aunins John G. (Chief Technology Officer & EVP)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-01	Stock Option (Right to Buy)	$26.20	A	69000	Acquired	2026-01-31	Common Stock (69000)	Direct

Footnotes

F1: The option vests as to 25% of the shares subject to the option on February 1, 2017, and as to an additional 6.25% of the total number of shares subject to the option upon the completion of each three consecutive months of service thereafter.